Zephyr AI
Zephyr AI leverages advanced machine learning and a vast real-world dataset to extract actionable insights from complex data, aiming to accelerate therapeutic development. Their platform integrates seamlessly into clinical workflows, offering tools for predictive modeling, AI-enabled companion diagnostics, cohort construction, risk stratification, and real-world evidence generation. Zephyr AI collaborates with biopharma, diagnostics, and research partners to improve decision-making across the therapeutic lifecycle, from discovery to commercialization. They are committed to precision medicine through scalable software and real-world intelligence, valuing patient-first impact, clarity from complexity, transparency, diverse perspectives, and urgent, purposeful action.
Zephyr AI
Zephyr AI leverages advanced machine learning and a vast real-world dataset to extract actionable insights from complex data, aiming to accelerate therapeutic development. Their platform integrates seamlessly into clinical workflows, offering tools for predictive modeling, AI-enabled companion diagnostics, cohort construction, risk stratification, and real-world evidence generation. Zephyr AI collaborates with biopharma, diagnostics, and research partners to improve decision-making across the therapeutic lifecycle, from discovery to commercialization. They are committed to precision medicine through scalable software and real-world intelligence, valuing patient-first impact, clarity from complexity, transparency, diverse perspectives, and urgent, purposeful action.
TL;DR
Founded: 2020
Headcount (approx.): 46
Core product: Multi-modal AI platform for precision medicine (AIM Suite, including AIM-Bx)
Industry: Biotechnology / Healthcare AI
Total funding: USD 129,500,000
Company Overview
Problem Domain
Translating fragmented clinical and genomic real-world data into validated, deployable precision medicine insights for drug development and diagnostics.
Founded
2020
Industry
Biotechnology
Tech Stack
Funding Track Record
USD 129,500,000
Round includes multiple investors (listed investors include AME Cloud Ventures, Allen Chao, BoxGroup, EPIQ Capital Group, Eli Lilly & Company Foundation, Jeff Skoll, Lerner Enterprises, Liquid 2 Ventures, M-Cor Holdings, MedStar Health, Revolution Growth).